文献速递复苏、休克与脓毒症

髓样细胞触发受体-1在脓毒症中的作用及临床研究现状

Triggering receptor expressed on myeloid cells-1 in sepsis, and current insights into clinical studies.
PubMed 文献 · Crit Care · 2024-01-09
一句话结论脓毒症和脓毒症休克患者sTREM-1水平升高,TREM-1通路是重要免疫应答 contributor,目前仅nangibotide进入临床试验并显示有希望的数据。

本文综述髓样细胞触发受体-1(TREM-1)通路及其重要配体在脓毒症中的作用。TREM-1激活导致促炎细胞因子、趋化因子产生和释放,并增加其自身表达及裂解释放的可溶性胞外部分(sTREM-1)循环水平。脓毒症和脓毒症休克患者sTREM-1水平升高,提示TREM-1参与该致命状态的免疫应答失调。自2001年首次在脓毒症中阻断TREM-1以来,动物模型中已建立多种潜在TREM-1抑制剂,但仅nangibotide进入临床试验,并显示对未来治疗脓毒症、脓毒症休克及COVID-19等其他炎症性疾病有希望的数据。本文讨论TREM-1通路和重要配体,并重点介绍新型抑制剂的开发及其靶向治疗各种炎症条件的临床潜力。

要点

  • 脓毒症和脓毒症休克患者sTREM-1水平升高,TREM-1被认为是该致命状态免疫应答不足的重要 contributor。
  • TREM-1激活导致促炎细胞因子、趋化因子产生和释放,并增加其自身表达及sTREM-1循环水平。
  • 自2001年首次在脓毒症中阻断TREM-1以来,动物模型中已建立多种潜在TREM-1抑制剂。
  • 仅nangibotide进入临床试验,并显示对未来治疗脓毒症、脓毒症休克及COVID-19等其他炎症性疾病有希望的数据。

证据类型、等级与局限

  • 综述,总结TREM-1通路及抑制剂临床研究现状;原文未报告局限性

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「适用人群与场景」「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「研究设计与关键结果」「对床旁实践的改变」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Triggering receptor expressed on myeloid cells-1 (TREM-1) is a pattern recognition receptor and plays a critical role in the immune response. TREM-1 activation leads to the production and release of proinflammatory cytokines, chemokines, as well as its own expression and circulating levels of the cleaved soluble extracellular portion of TREM-1 (sTREM-1). Because patients with sepsis and septic shock show elevated sTREM-1 levels, TREM-1 has attracted attention as an important contributor to the inadequate immune response in this often-deadly condition. Since 2001, when the first blockade of TREM-1 in sepsis was performed, many potential TREM-1 inhibitors have been established in animal models. However, only one of them, nangibotide, has entered clinical trials, which have yielded promising data for future treatment of sepsis, septic shock, and other inflammatory disease such as COVID-19. This review discusses the TREM-1 pathway and important ligands, and highlights the development of novel inhibitors as well as their clinical potential for targeted treatment of various inflammatory conditions.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Theobald V, Schmitt FCF, Middel CS, et al. Triggering receptor expressed on myeloid cells-1 in sepsis, and current insights into clinical studies. Crit Care. 2024. PMID: 38191420. doi:10.1186/s13054-024-04798-2

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。